NCT03611413 is a clinical trial of ERAS care in Colon Perforation, sponsored by Antonio Arroyo Sebastian.

Who is sponsoring NCT03611413?

NCT03611413 is sponsored by Antonio Arroyo Sebastian.

What drugs are being tested in NCT03611413?

Interventions in NCT03611413: ERAS care.

What condition does NCT03611413 study?

NCT03611413 studies Colon Perforation.

Is NCT03611413 still recruiting?

NCT03611413 is currently completed. Last updated 8 August 2018.

Last reviewed 2018-08-08 · How we verify

NCT03611413

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility and Effects of an Enhanced Recovery vs Conventional Care After Emergency Colon Surgery for Patients With Left Colon Perforation.

Completed Last updated 8 August 2018

What this trial tests

trial testing ERAS care in Colon Perforation in 50 participants. Completed in 30 June 2017.

Timeline

1 March 2014

Primary endpoint
30 June 2017

30 June 2017

Quick facts

Lead sponsor	Antonio Arroyo Sebastian
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 March 2014
Primary completion	30 June 2017
Estimated completion	30 June 2017

Drugs / interventions tested

ERAS care

Conditions studied

Colon Perforation — all drugs for Colon Perforation →

Sponsor

Antonio Arroyo Sebastian — full company profile →

Who can join

Eligibility, any sex, with Colon Perforation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study was designed with a prospective cohort of all patients undergoing urgent surgery for left colon perforation between March 2014 and June 2017 who were treated according to a specific ERAS programme (ERAS group/29 patients). This group was compared with a historic case-matched control group with conventional care (CC group/21 patients). The main endpoints were postoperative 30-day morbidity, length of postoperative hospital stay, rate of readmission within 30 days, and mortality. The inclusion criteria were patients over 18 years old with a low-moderate risk of mortality according to a Peritonitis Severity Score (PSS) between 6-11 points.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03611413 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Antonio Arroyo Sebastian
Last refreshed: 8 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03611413.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing